Kistler Tiffany Companies LLC Lowers Holdings in Amgen, Inc. (NASDAQ:AMGN)
Kistler Tiffany Companies LLC trimmed its position in Amgen, Inc. (NASDAQ:AMGN) by 1.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,424 shares of the medical research company’s stock after selling 137 shares during the period. Amgen makes up about 1.0% of Kistler Tiffany Companies LLC’s holdings, making the stock its 19th biggest position. Kistler Tiffany Companies LLC’s holdings in Amgen were worth $2,995,000 at the end of the most recent reporting period.
A number of other large investors have also recently bought and sold shares of AMGN. BlackRock Inc. lifted its holdings in Amgen by 3.4% in the second quarter. BlackRock Inc. now owns 47,717,316 shares of the medical research company’s stock valued at $8,793,346,000 after acquiring an additional 1,585,911 shares during the period. Morgan Stanley lifted its holdings in Amgen by 0.5% in the second quarter. Morgan Stanley now owns 6,753,145 shares of the medical research company’s stock valued at $1,244,470,000 after acquiring an additional 34,674 shares during the period. Nuveen Asset Management LLC lifted its holdings in Amgen by 1,334.9% in the second quarter. Nuveen Asset Management LLC now owns 4,942,807 shares of the medical research company’s stock valued at $910,860,000 after acquiring an additional 4,598,329 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in Amgen by 9.4% in the second quarter. Price T Rowe Associates Inc. MD now owns 2,780,461 shares of the medical research company’s stock valued at $512,383,000 after acquiring an additional 239,576 shares during the period. Finally, Parametric Portfolio Associates LLC lifted its holdings in Amgen by 7.0% in the third quarter. Parametric Portfolio Associates LLC now owns 2,353,360 shares of the medical research company’s stock valued at $455,399,000 after acquiring an additional 154,094 shares during the period. Hedge funds and other institutional investors own 76.58% of the company’s stock.
A number of equities research analysts have commented on AMGN shares. Sanford C. Bernstein started coverage on Amgen in a report on Monday, October 14th. They issued an “outperform” rating for the company. Leerink Swann raised their target price on Amgen from $189.00 to $205.00 and gave the company a “market perform” rating in a report on Wednesday, October 30th. JPMorgan Chase & Co. reissued a “hold” rating on shares of Amgen in a report on Monday, September 30th. Raymond James started coverage on Amgen in a report on Monday, December 23rd. They issued a “market perform” rating for the company. Finally, Argus raised their target price on Amgen from $240.00 to $265.00 and gave the company a “buy” rating in a report on Monday, December 9th. Eleven research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Amgen presently has a consensus rating of “Buy” and a consensus target price of $235.39.
Shares of NASDAQ:AMGN traded up $3.08 during midday trading on Tuesday, hitting $240.00. 2,169,776 shares of the stock were exchanged, compared to its average volume of 1,877,842. The stock has a market cap of $141.57 billion, a P/E ratio of 16.67, a PEG ratio of 2.07 and a beta of 1.11. The company has a current ratio of 2.89, a quick ratio of 2.59 and a debt-to-equity ratio of 2.54. Amgen, Inc. has a twelve month low of $166.30 and a twelve month high of $244.99. The company has a 50 day moving average price of $238.06 and a 200-day moving average price of $208.24.
Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, October 29th. The medical research company reported $3.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.53 by $0.13. The business had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.63 billion. Amgen had a return on equity of 80.26% and a net margin of 34.48%. The business’s revenue was down 2.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $3.69 EPS. On average, equities research analysts expect that Amgen, Inc. will post 14.58 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 14th will be paid a dividend of $1.60 per share. This represents a $6.40 annualized dividend and a dividend yield of 2.67%. The ex-dividend date of this dividend is Thursday, February 13th. This is an increase from Amgen’s previous quarterly dividend of $1.45. Amgen’s payout ratio is 40.28%.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
See Also: Trade War
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.